Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Chonluten and Semax — mechanism, side effects, legal status, and pricing.
A short synthetic peptide bioregulator (Glu-Asp-Gly) from the Khavinson family, marketed for bronchial/lung epithelium support. Evidence is largely Russian-language and preclinical.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension for metabolic stability. It was developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and registered as a drug in Russia in 1994. It is not FDA-approved.
Chonluten
Semax
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Chonluten
Semax
COA corpus from Disclosed Labs — independently tested batches only.
Chonluten
4
COAs
99.6%
Avg purity
2
Labs
Semax
82
COAs
99.5%
Avg purity
16
Labs
Primarily Russian institutional studies; no large independent controlled human trials.
Semax's evidence base is primarily Russian-language clinical literature. Gusev, Skvortsova and colleagues reported improved neurological recovery in acute hemispheric ischemic stroke when Semax was added to conventional therapy (Zh Nevrol Psikhiatr, 1997; PMID 11517472), and subsequent Russian studies extended use to cerebrovascular insufficiency (PMID 15792140). Preclinical work by Dolotov, Myasoedov and colleagues demonstrated that intranasal Semax rapidly elevates BDNF protein and TrkB activation in rat hippocampus and basal forebrain (Brain Res 2006, PMID 16996037; J Neurochem 2006, PMID 16635254). Genome-wide transcriptional analysis by Medvedeva et al. in rat focal ischemia showed Semax modulates a broad panel of immune-response and vascular-system genes (BMC Genomics 2014, PMID 24661604). Western evidence is limited; Semax has not been evaluated by the FDA and has no pivotal trials in the US or EU.
Key references
Chonluten (Immune) and Semax (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing